Scrip
20 August 2009
Nancy Faigen
A US federal judge has upheld the validity of Merck & Co's compound patent on its top-selling asthma drug, Singulair (montelukast sodium), in a ruling that prevents Teva Pharmaceutical Industries from marketing a generic until August 2012.
In an August 19th decision,
Judge Garrett Brown...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Teva withdraws US challenge to Merck & Co's Singulair patent
- US Patent Office sides with Merck & Co on validity of Singulair patent
- US court upholds Evista patents through 2014, blocking Teva generic
- US court rules for Teva, claiming Merck & Co's Temodar patent is unenforceable
COMMENT
Other Informa Comment
EVENTS
17 March 2010
Berlin, Germany
17 March 2010
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
